Objective: There is widespread public concern about fairness in sports. Blood doping undermines fairness and places athletes' health at risk. The purpose of this study was to examine the prevalence of abnormal hematologic profiles in elite cross-country skiers, which may indicate a high probability of blood doping.
INTRODUCTION
Worldwide publicity related to the 3 "positive" doping cases after use of darbepoetin alfa (Aranesp; Amgen, Thousand Oaks, CA) during the 2002 Winter Olympics in cross-country skiing, recent headlines on anabolic steroid use in professional baseball, and reports of blood doping in other endurance sports underscore the public's concern for fairness in sports. Blood doping is very effective and can move a skier in 30th place to the medal podium. In a World Cup or Olympic cross-country ski race, the top 50 athletes typically finish within 10% of the winning time. Blood doping can provide up to a 10% enhancement of performance, making it by far the most effective way to manipulate results in endurance sports. 1, 2 The performance benefit of blood doping practices is dependent on the extent of the expansion in erythrocyte mass. This implies that athletes with the lowest natural hemoglobin values would have the largest potential benefit. In recombinant erythropoietin administration trials, an 8% increase in erythrocyte mass, corresponding to approximately 1 g per 100-mL increase in hemoglobin concentration, has led to a 2 to 5% increase in endurance performance. 1, 2 Even greater enhancements of performance can be achieved by further expansion of erythrocyte mass coupled with temporarily increased plasma volumes to stay below the hemoglobin limits currently established by several sports federations. As indirect evidence of the performance-enhancing effects of blood doping, the 3 skiers who tested positive for darbepoetin alfa (Aranesp) in the Salt Lake 2002 Winter Olympics had won 9 medals. In previous Olympic Games and World Championships, the same 3 skiers had garnered 38 medals.
In 1972, Ekblom et al 3 demonstrated the efficacy of blood transfusions on performance, but rumors and reports of transfusion use in endurance sports did not surface until the late 1970s. By the late 1980s, recombinant erythropoietin became available for renal failure patients and was soon being used to enhance athletic performance based on documented use of recombinant erythropoietin in cycling competitions and indirectly based on the abnormal increase in hemoglobin values among skiers. 4 Today, blood doping may be accomplished through a variety of methods, including homologous/autologous transfusions, cross-linked hemoglobin products, recombinant erythropoietin, darbepoetin, and epoetin delta (Dynepo; Aventis Pharmaceuticals, Bridgewater, NJ). 5 The use of these methods is supported by the reported increase in mean hemoglobin concentrations among elite skiers in the 1990s by more than 1 standard deviation. 4 To date, the governing organizations in endurance sports have not applied all of the latest methods and protocols available to identify doping practices. For example, despite straightforward, ironclad detection procedures, testing for homologous blood transfusions has only been performed 4 times: at the 1989, 1991, 1995, and 1999 Nordic World Championships and at the 1994 Winter Olympics.
When large monetary rewards for a top finish and the efficacy of blood doping are coupled with international sports organizations' ineptitude or unwillingness to deal with this issue, the temptation for athletes to dope is great. Under these circumstances, only the truly exceptional athlete is able to win "clean." This situation creates a Faustian choice for the athlete: either compete with integrity and lose or cheat and win.
The purpose of this study was to estimate the prevalence of abnormal hematologic profiles in elite crosscountry skiers and to describe their distribution in race results. While we recognize that these abnormalities could be due to extremely rare genetics, such as an erythropoietin receptor gene mutation, 6 we contend that the vast majority of very abnormal profiles are due to blood doping practices.
MATERIALS AND METHODS
Using flow cytometry, we analyzed the characteristics of erythrocytes and reticulocyte indices in competitors participating in the 2001 Nordic World Ski Championships. Blood samples were obtained as part of the routine International Ski Federation (FIS) testing procedures. Approximately 10% of the skiers were chosen prior to each race for measurement of hemoglobin concentration. One half of the selections were derived from the top 20 ranked skiers, whereas the other half was made up of random selections from the rest of the field (Fig. 1) . Venous blood was drawn on EDTA and tested for hemoglobin concentration (hemoglobin test system; HemoCue, Ängelholm, Sweden). Those skiers with values higher than 17.5 g/dL for men and 16.0 g/dL for women were not allowed to start that particular race. At the time of the measurement, all skiers tested were allowed to start. The tube containing the remaining sample had a bar code number affixed for identification and anonymity. The medical supervisor assigned to the event (I.L.) retained the code list and was not involved in any sample analysis.
We obtained 203 blood samples from 146 athletes, with many athletes being tested more than once. We obtained samples from 68% of all competitors and 92% of those finishing in the top 10 places. The samples were analyzed within 8 hours on an Advia 120 flow cytometry hematology analyzer (Bayer, Tarrytown, NY). The instrument was calibrated before taking the measurements each day. The samples were analyzed in duplicate, and the results were averaged. The correlation between hemoglobin values from the HemoCue system and the Advia 120 was 0.93. However, there were some individual hemoglobin measurements on the Advia 120 that were greater than the FIS hemoglobin limits. Variables measured included hemoglobin concentration (colorimeter channel absorption) and reticulocyte number (Oxazine 750 stain in flow cytometry channel). The manufacturer's percent coefficient of variation is less than 1% for hemoglobin concentration on both colorimeter and flow cytometry channels and 13% for reticulocyte values.
Results were classified as "highly abnormal" (>3 SD), "abnormal" (>2 SD but <3 SD), or "normal" based on the extent to which a result varied from the mean of the endurance athletic population (Table 1) . Data from the blood doping tests at the 1989 World Nordic Ski Championships in Lahti, Finland, 4 and the data from endurance athletes residing at sea level obtained from the International Olympic Committee Erythropoietin 2000 project were used to establish mean and distribution reference values. The data collected in the 1989 World Championships included hemoglobin concentration (hematocrit and serum erythropoietin) and came from those athletes selected to undergo doping tests following a common practice: all of the top 4 skiers and 2 randomly selected skiers. Data from the Erythropoietin 2000 project were used as reference values for reticulocytes and provided additional reference values for hemoglobin.
Based on these results, the expected prevalences of highly abnormal, abnormal, and normal were less than 0.3%, less than 2.5%, and 97.5%, respectively. Results classified as highly abnormal (>3 SD) are suspected of resulting from blood doping practices, while samples classified as abnormal (>2 SD) are in an intermediate zone where the result could be due to doping, rare genotype, or recent sustained exposure to hypoxia. [6] [7] [8] [9] The hematologic results designated as normal also could come from skiers who have been doping but have stayed within 2 standard deviations of the mean values for the endurance athlete population. Once classified, the hematologic results were matched to the race results. Samples of athletes finishing in the top 50 places in 9 individual races were used for this report.
Ethical Considerations
The blood samples were obtained for precompetition hemoglobin testing following the rules of the FIS. After the routine testing procedures had been completed, the remaining samples were provided to the authors so that they could examine the variability of hemoglobin and reticulocyte values in elite cross-country skiers to be used in a report to the FIS Council. The FIS Medical Committee accepted the plan to publish the article in a scientific journal.
RESULTS
Of all of the athletes sampled and finishing within the top 50 places, 17% had highly abnormal hematologic profiles, 19% were abnormal, and 64% were normal. Of the medal winners sampled, 50% had highly abnormal hematologic profiles, and 33% of those finishing from 4th to 10th place also had highly abnormal values (Fig.  2) . These results are in marked contrast to those of skiers finishing from 41st to 50th place, of whom only 3% had highly abnormal hematologic profiles.
The frequency distributions for hemoglobin concentration are skewed, with a subset of athletes centered close to the highest values allowing race participation (Fig. 3) . As indicators of accelerated erythropoiesis, the highest reticulocyte hemoglobin values for men and women were 4.6 and 3.6 (pg), respectively, which are 5.5 and 3.9 standard deviations greater than the mean using the Erythropoietin 2000 project data as a reference (Table 2) .
DISCUSSION
Among the athletes who placed within the top 50 in the races in the World Ski Championships, 36% had either highly abnormal or abnormal hematologic profiles. Athletes with highly abnormal hematologic profiles were at the top of the results list and won half of the medals and a third of the remaining top 10 places when the expected frequencies indicate that less than 0.3% would have been predicted to have highly abnormal values.
It is extremely unlikely that the use of either normobaric or hypobaric hypoxia explains these results since the largest effects observed in published work on this subject in endurance athletes are of much smaller magnitude. 7 Indeed, some investigators argue that there is little or no erythropoietin stimulation from the levels of hypoxia used by endurance athletes. 8, 9 We were not able to obtain optimal reference values for hemoglobin and reticulocyte values. The obvious problem was the same as for the core of this study: how to identify those elite cross-country skiers who had or had not been blood doping. Our earlier study had shown that the mean hemoglobin values in past years had increased to the same levels as the highest values at the World Championships in 1989, which cannot be explained physiologically. In 1989, the hemoglobin values of the elite skiers were below the population means, which is concordant with earlier observations and explained by increased plasma volumes noted in endurance athletes. 10 However, the sample size in the 1989 World Championships was low (6 skiers per race), the analyses were conducted with different equipment, and no flow cytometry measurements (to determine rates of erythropoiesis) were obtained. The best available option was to use these data and data from endurance athletes residing at sea level (same altitude as the Championships) who participated in the Erythropoietin 2000 project, where recombinant erythropoietin use was controlled. Because a statistical definition of abnormality was used, different reference values would alter the prevalence of abnormal hematologic profiles. However, the overall message of this report would not be altered. A comparison of the prevalence of highly abnormal values among athletes finishing from 1st to 10th with those finishing 41st to 50th supports this conclusion. If the highly abnormal values were due to inappropriately strict limits, then they should be equally distributed throughout the race results.
At present, international federations follow the International Olympic Committee medical code and only recognize the presence of a banned substance in urine as proof of doping. 11 However, the confirmation tests of transfusions or the use of cross-linked hemoglobin products currently are based on blood samples. Furthermore, urine testing for recombinant erythropoietin is logisti- cally and technologically difficult. The fact that darbepoetin was identified in 3 cross-country skiers in the recent Winter Olympics in Salt Lake City only a few months after it was made available to medical practitioners indicates how quickly performance-enhancing drugs are introduced into competitive sports. While darbepoetin has a longer half-life and is therefore more likely to be detected, recombinant erythropoietin is cleared from the body to undetectable levels in less than 7 days and usually in 1 to 3 days. A new form of erythropoietin, epoetin delta (Dynepo) is now available and is being produced in human cell lines, making it virtually indistinguishable from endogenous erythropoietin. In addition, introduction of simian erythropoietin DNA into primates by adenovirus has produced an increase in erythrocyte mass. 12 Both the advent of epoetin and erythropoietin gene "therapy" will obviate current detection methods and make it obvious that effective doping controls will have to rely to a greater extent on indirect markers, such as hematologic profiles, as sufficient evidence for a federation to take action. The rationale to continue using the current ineffective controls should be questioned. The new formulations of erythropoietin leave athletes (who are very aware of the significant performance benefits derived from doping and who realize that testing procedures are ineffective) with the choice of competing "clean" and likely losing or doping to be able to compete with "those other cheaters" who will not be caught by existing controls.
A test program (Safe and Fair Event [SAFE] program) that indicates blood doping with a high degree of probability has been used for the past 3 years in the International Skating Union. The program is inexpensive compared with standard doping controls, and results can be quickly obtained in all competing athletes. Specific confirmation and/or obligatory follow-up tests are effectively targeted at those athletes with some evidence suggesting blood doping. Application of this system in a longitudinal fashion would create a "hematologic passport" and further increase the efficacy of the program. In the International Skating Union, the incidence of highly abnormal test results has decreased from 13% in the first season that the program was implemented to 3 to 4% in subsequent seasons.
An important public health concern is that performance-enhancing methods used by elite athletes will < FIG. 2. This figure depicts the classification of the hematologic profiles in the 9 races at the 2001 Lahti World Nordic Championships. Each of the 9 races is represented by a column. The hematologic result for an athlete is placed in the position of their race result (1st to 50th) in each column. A black oval indicates a "highly abnormal" (>3 SD) hematologic profile in the skier who obtained that race result. A speckled oval indicates an "abnormal" (>2 SD but <3 SD) hematologic profile in the skier who obtained that race result. A white oval indicates a "normal" hematologic profile in the skier who obtained that race result. A blank area indicates that a sample was not obtained from the athlete who achieved that race result. (Location of the ovals within a row was altered to maintain the prevalence of each classification for each place while obscuring the identity of the individual.) eventually spread to young people, who view the elite competitors as role models. Evidence of this process is seen in studies indicating that anabolic steroid use is now prevalent among high school athletes. 13, 14 Another concern is that there may be a loss of interest in and support of sports participation if children and their parents conclude that the best athletes are doping and that success in sports is a function of titrating banned medicines with real health risks. Furthermore, participation in exercise and competitive sports in adolescence strongly influ- ences physical activity throughout life. [15] [16] [17] Since interest in regular exercise is instilled in childhood, assuring safe and fair conditions in sports participation is in the best interest of society.
CONCLUSIONS
The results of this study suggest that blood doping is both prevalent and highly effective in cross-country ski racing. In addition, these results indicate that currently applied testing programs are ineffective in either deterring or detecting the use of blood doping practices. Because of the efficacy of blood doping and ineffective deterrence and detection, it is likely that blood doping is a common practice in many endurance sports and perhaps other sports only minimally dependent on aerobic fitness. Thus, 2 important concerns are the fairness of elite competitive sports and safety. Youth in particular may be at risk by emulating role models who feel that they must dope to win. In an attempt to develop higher ethical perspectives in the next generation of competitors, effective detection and deterrence of current and future doping practices are needed in all endurance sports and perhaps others also. These procedures are likely to be based on longitudinal screening of blood using indirect methods and confirmation with either direct or indirect evidence, depending on the doping agent.
